title: Biotechnology and genetic engineering in the new drug development. Part II. Monoclonal antibodies, modern vaccines and gene therapy.
abstract: Monoclonal antibodies, modern vaccines and gene therapy have become a major field in modern biotechnology, especially in the area of human health and fascinating developments achieved in the past decades are impressive examples of an interdisciplinary interplay between medicine, biology and engineering. Among the classical products from cells one can find viral vaccines, monoclonal antibodies, and interferons, as well as recombinant therapeutic proteins. Gene therapy opens up challenging new areas. In this review, a definitions of these processes are given and fields of application and products, as well as the future prospects, are discussed.
authors.affiliation: Department of Bioorganic Chemistry, Faculty of Chemistry, Wrocław University of Technology, Wyb. Wyspiańskiego 27, PL 50-370 Wrocław, Poland. s.lochynski@wsf.wroc.pl; mflibrow@cyf-kr.edu.pl.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Stryjewska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Kiepura
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Librowski
authors.forename: Stanisław
authors.initials: S
authors.lastname: Lochyński
mesh_terms: D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000235:genetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000096:biosynthesis / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use; D001709:Biotechnology / Q000379:methods*; D003001:Cloning, Molecular; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000096:biosynthesis / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D005818:Genetic Engineering; D015316:Genetic Therapy; D005822:Genetic Vectors; D017325:Hepatitis B Vaccines / Q000096:biosynthesis / Q000627:therapeutic use; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000235:genetics / Q000628:therapy; D007252:Influenza Vaccines / Q000096:biosynthesis / Q000627:therapeutic use; D011054:Poliovirus Vaccine, Inactivated / Q000096:biosynthesis / Q000627:therapeutic use; D034622:RNA Interference; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000627:therapeutic use; D016511:Severe Combined Immunodeficiency / Q000235:genetics / Q000628:therapy; D014614:Vaccines, Synthetic / Q000096:biosynthesis* / Q000235:genetics / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D017325:Hepatitis B Vaccines; D007252:Influenza Vaccines; C472675:PEDIARIX; D011054:Poliovirus Vaccine, Inactivated; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D000074323:Alemtuzumab